StreetAlpha
13F holdings · Q3 2026

Paradigm Biocapital Advisors

New York, NY · files as Paradigm Biocapital Advisors LP
Know the moment Paradigm Biocapital Advisors filesYou follow Paradigm Biocapital Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1855655

Paradigm Biocapital Advisors reported 30 stocks worth $5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (25.4%), GMAB (10.0%) and EWTX (8.7%). Compared with Q2 2026, the fund opened new positions in BBIO, OBX and GPCR, added to GMAB, EWTX and SYRE, trimmed RVMD, BLTE and TARS and sold out of ALNY, EYPT and MPLT.

Latest filing: what Paradigm Biocapital Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
8 new13 added6 trimmed6 sold outBought about $861M · sold about $1.3B
New 8
See all 8 →
Added 13
See all 13 →
Trimmed 6
See all 6 →
Sold out 6
  • Nuvalent Inc$732M
  • Apogee Therapeutic$209M
  • ALNY$144M
  • EYPT$41.3M
  • MPLT$24.6M
See all 6 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$5B−5.8% vs last quarter
Stocks held308 new · 6 sold out
Top 5 weight58.1%fairly concentrated
Turnover43%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RVMD
Revolution Medicines Inc
$1.3B25.4%6.2M−142K (−2%)8 of 8
2
GMAB
Genmab A/s
$504M10.0%14.1M+1M (+8%)5 of 8
3
EWTX
Edgewise Therapeutics Inc
$438M8.7%10.8M+563K (+6%)8 of 8
4
SYRE
Spyre Therapeutics Inc
$397M7.9%4.5M+617K (+16%)8 of 8
5
INSM
Insmed Inc
$308M6.1%2.7M+1.4M (+103%)4 of 8
6
MBX
Mbx Biosciences Inc
$221M4.4%3.8M+1.3M (+50%)2 of 8
7
ORKA
Oruka Therapeutics Inc
$208M4.1%2.5M+349K (+16%)5 of 8
8
BLTE
Belite Bio Inc
$194M3.9%1.1M−91K (−7%)3 of 8
9
TARS
Tarsus Pharmaceuticals Inc
$181M3.6%2.3M−474K (−17%)8 of 8
10
TNGX
Tango Therapeutics Inc
$174M3.5%7M+604K (+10%)4 of 8
🔒 20 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
NUVALENT INC
$732M5.9M
APOGEE THERAPEUTICS INC
$209M1.6M
ALNY
Alnylam Pharmaceuticals Inc
$144M480K
EYPT
Eyepoint Pharmaceuticals Inc
$41.3M2.9M
MPLT
Maplight Therapeutics Inc
$24.6M686K

🔒 Free account: see all 6.

Reported value

last 8 quarters
$2.9BQ4 '24
$2.2BQ1 '25
$2.3BQ2 '25
$3.4BQ3 '25
$3.7BQ4 '25
$4.9BQ1 '26
$5.3BQ2 '26
$5BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Paradigm Biocapital Advisors 13F FAQ

What does Paradigm Biocapital Advisors own?

Paradigm Biocapital Advisors reported 30 stocks worth $5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (25.4%), GMAB (10.0%) and EWTX (8.7%). The table above lists every position in the filing (the top 10 without an account).

What did Paradigm Biocapital Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 8 new positions, 13 added to, 6 trimmed and 6 sold out. New positions include BBIO, OBX and GPCR. It sold all of ALNY, EYPT and MPLT.

When will Paradigm Biocapital Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Paradigm Biocapital Advisors's portfolio worth?

The Q3 2026 filing reports $5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.